Natural weight management: PLT Health Solutions’ Slendacor ingredient gains Japanese fat burner patent
08 Jan 2024 --- PLT Health Solutions reveals an expansion of its intellectual property with a new patent for its Slendacor weight management complex. According to the company, the patent is based on recent clinical research showing how Slendacor’s thermogenic properties promote weight loss and body shaping.
The patent spotlights Slendacor’s ability to enhance lean body mass and transform white adipose tissue (WAT) into metabolically active brown (BAT) or beige adipose tissue (BeAT). WAT stores energy in the form of large lipid droplets but has a lower amount of mitochondria and larger globules than BAT or BeAT and is, therefore, not as easily broken down in the body.
Slendacor, also known in some markets as Slimvance, is a blend of three standardized spice extracts — turmeric, drumstick leaves and curry leaves. Japan is the first country to grant a patent for this thermogenic effect.
“We are pleased that the Japanese patent office has chosen to recognize the quality and innovative findings of the clinical science surrounding Slendacor,” says Seth Flowerman, president and CEO of PLT Health Solutions. “Our customers can be confident of the groundbreaking benefits and efficacy they can offer consumers with Slendacor.”
Natural weight management
With the introduction of weight management medications, such as semaglutide, some companies are looking to create products that can work hand-in-hand with the new medications. However, some experts are looking at the benefits of natural alternatives to prescription drugs.
PLT Health Solutions points out that three human clinical trials and several preclinical studies support the product’s efficacy. The company notes that a 16-week study in 2018 demonstrated significant weight loss starting as early as two weeks into the trial, with participants losing an average of nearly 12 pounds and two inches off their waist without losing lean body mass.
More recent preclinical studies have unveiled a novel mechanism of action where Slendacor stimulates the expression of uncoupling protein 1 (UCP1) — a mitochondrial membranous protein in white adipose tissue that helps to “burn” the fat away. This finding is significant because BAT and BeAT cells are associated with leanness in humans.
“Part of delivering best-in-class ingredient solutions is the ability to develop truly novel inventions backed by intellectual property on the innovation and supported by high-quality clinical science,” Flowerman underscores.
“Our new data shows that Slendacor is not just limiting the formation of new fat cells, but also increasing the metabolic activity of existing fat cells,” explains Jennifer Murphy, the company’s director of innovation and clinical development. “The browning of white adipose tissue means that those cells are now burning energy that may otherwise have been stored as fat.”
Improving RMR
Another recent clinical trial looked at Slendacor’s impact on resting metabolic rate (RMR) — the rate at which a person burns calories while resting. The company highlights that participants showed a 15.2% increase in resting energy expenditure after a single daily dose. Moreover, calorie-burning heightened within an hour of intake from the first day of the study.
The trial also monitored heart rate, blood pressure and mood and found that Slendacor, unlike other thermogenic agents, does not stimulate heart rate or blood pressure, marking it as a non-stimulant thermogenic solution.
“Healthy weight management has long focused on reducing intake, however, we know that metabolism is an equally important part of the equation for healthy and sustainable changes in body weight,” Murphy concludes.
“These new data help us understand Slendacor as an integral part of a holistic health management program, providing support for both healthy body weight, as well as improved overall cardiometabolic health, opening up a range of new applications and use occasions for the Slendacor ingredient.”
Edited by William Bradford Nichols
